Biotech Startups

Hendrix Genetics develops and supplies animal breeding genetics and technology across multiple species including turkeys, laying hens, poultry, swine, salmon, trout, and shrimp to address global food demand. The company operates through a portfolio of 15 genetic brands across more than 25 countries worldwide.

1 investor

Henlez is an early-stage biotech company working in the dermatology space.

1 investor

Hepta develops LiquidTransformer, an AI platform for analyzing cell-free DNA fragments in blood to detect chronic disease molecular signals. The platform uses transformer-based models with attention mechanisms to identify disease biomarkers from liquid biopsy samples.

1 investor

Heqet Therapeutics is a pre-clinical stage biotech developing non-coding RNA-based therapies for cardiovascular diseases, with a focus on acute myocardial infarction. Its compounds target multiple pathways through the upregulation of certain non-coding RNAs to promote heart regeneration.

1 investor

Hera BioLabs provides gene editing technologies and cell line development services for drug discovery researchers. The company offers custom cell line platforms, animal models, and bioprocessing solutions using transposase technology and proprietary tools like the SRG Rat platform and CleanCut GS CHO system.

1 investor

Herikîn develops automation platforms for biomanufacturing, focusing on simplified RNA production and processing. The company serves research labs and bioproduction facilities seeking scalable, accessible tools for biological molecule manufacturing.

1 investor

Hermes Biosciences develops a benchtop system for isolating extracellular vesicles and exosomes from bodily fluids and cell culture media for research and clinical applications in oncology, degenerative disease, and regenerative medicine.

1 investor

Herophilus develops neurological drug discovery by combining human brain models, scaled biology, and machine learning to identify and develop novel drugs for complex brain diseases. It operates in the biotech and neuroscience drug development space.

1 investor

Hesperos develops "Human-on-a-Chip" organ-on-a-chip platforms, offering custom multi-organ models (up to 5 organ or tissue types) with functional readouts such as gene expression and electrophysiology. The systems provide pre-clinical efficacy and toxicity data on drugs and chemicals for the pharmaceutical, cosmetic, and food industries.

1 investor

HGS BioScience produces liquid and powder agricultural products containing extracted humates to improve nutrient uptake and crop yield for farmers. The company offers formulations with fulvic and humic acids, sea plant extracts, and kelp-based solutions designed to enhance plant stress tolerance and performance throughout the growing season.

1 investor

PACT develops earth-positive bio-based materials for fashion and consumer brands, focusing on scalable, sustainable alternatives to conventional materials. The company operates a research and development laboratory and pilot manufacturing facilities to scale up its biomaterials for partner brands.

1 investor

Hifas da Terra is a biotechnology company that develops mushroom-based natural health supplements, including products for stress, sleep, digestive health, menopause, and vitamin D. It sells directly to consumers and works with health professionals, positioning itself in the nutraceutical and wellness market.

1 investor

High Q Technologies builds quantum-enabled scientific instruments that apply microwave quantum optics techniques to electron paramagnetic resonance (EPR) spectroscopy for ultra-high sensitivity biophysical and chemical analysis. Its technology targets protein structure determination and drug discovery, serving researchers and pharmaceutical development.

1 investor

HighCape Partners is a venture capital firm investing in connected health, medical devices, and biotechnology companies. The firm provides capital and operational expertise to early-stage and growth-stage life sciences companies.

1 investor

H.I.G. HealthBridge Capital Partners is a growth equity investment fund focused on healthcare companies across medical devices, biopharmaceuticals, digital health, diagnostics, and related services.

1 investor

Higher Steaks uses cell culture techniques to grow meat products from animal cell samples without traditional animal farming. The company serves food producers and consumers seeking cultivated meat alternatives.

1 investor

Highfield Diagnostics develops point-of-care diagnostic sensors using laser-based technologies on paper substrates, targeting detection of diseases like tuberculosis and leishmaniasis in resource-limited settings. The company applies laser engineering and microfluidics expertise to create affordable, low-cost diagnostic tests.

1 investor

Highlight Therapeutics is a biotech company developing therapeutic treatments. The page does not provide specific details about the company's focus area, customer base, or geographic market.

1 investor

HIGHR produces an organic glossing lip oil that blends natural oils and butters as alternatives to silicone and petroleum-based ingredients, packaged in recyclable glass and made in the USA. The product line serves consumers seeking natural beauty products with sustainable packaging.

1 investor

HighTechXL is an organization that supports deep-tech venture creation by sourcing and evaluating emerging technologies from research institutions and tech companies, then matching them with co-founders to establish new ventures. The organization focuses on deep-tech innovations that address significant societal challenges.

1 investor

HighTide Therapeutics is a biopharmaceutical company developing multifunctional therapies targeting cardiovascular-kidney-metabolic diseases. The company has a globally integrated pipeline with lead asset HTD1801 designated as a Fast Track and Orphan Drug candidate by the FDA.

1 investor

HISHOH Biopharma develops and commercializes pharmaceutical compounds using proprietary drug discovery technology, supported by a team with extensive R&D experience from Japanese pharmaceutical companies and supported by venture capital investors.

1 investor

Histide is a biotech intellectual property platform company developing a class of non-mutagenic extracellular therapeutic agents called Cell Recoding Molecules (CRM), which act on the cell's microenvironment to redirect cell fate for tissue regeneration and disease treatment. Its Recoding Therapeutics platform targets applications across pharmaceuticals, medical devices, and medical cosmetics, with a pipeline spanning five strategic therapeutic areas.

1 investor

HLB PEP manufactures and supplies peptide pharmaceutical ingredients, producing generic peptides and custom-synthesized peptides at a GMP facility. It also runs catalog research peptides (hormones, neuropeptides, antibiotic peptides, neurotoxins) and pursues new drug candidate discovery for licensing and commercialization.

1 investor